G1 Therapeutics Inc Stock News

G1 Therapeutics (GTHX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Acadian Asset Management LLC purchased a new position in shares of G1 Therapeutics Inc (NASDAQ:GTHX) in the first quarter, according to the company in its most recent 13F filing with the Securities an

Rhumbline Advisers increased its position in G1 Therapeutics Inc (NASDAQ:GTHX) by 4.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Com

Jun 09, 2020 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Our research report “Estrogen and...

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1) Adaptimmune Therapeutics PLC...

G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that the company has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to

- Trilaciclib significantly reduced myelosuppression and need for related supportive care interventions for patients with small cell lung cancer (SCLC) receiving chemotherapy -.

G1 Therapeutics, Inc. (NASDAQ:GTHX) Q1 2020 Earnings Conference Call May 06, 2020, 16:30 ET Company Participants Jeff Macdonald - Senior Director, IR & Corp

On today's call, Mark Velleca, Chief Executive Officer; Raj Malik, Chief Medical Officer and Senior Vice President of R&D; and Jen Moses, Chief Financial Officer will provide an overview of the quarte

G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today provided a corporate and financial update for the first quarter ended March 31, 2020. “We have activated business cont

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week Highs May 5) • Adverum Biotechnologies...

Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...

G1 Therapeutics (NASDAQ:GTHX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Saturday, Zacks.com reports. The firm presently has a $15.0

RESEARCH TRIANGLE PARK, N.C., April 29, 2020 -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and.